Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
|
Add to portfolio |
|
|
|
| Price: |
$30.08
| | Metrics |
| OS: |
54.6
|
M
| |
5
|
% ROE
|
| Market cap: |
$1.64
|
B
| |
14
|
% ROIC
|
|
Net cash:
|
$189
|
M
| |
$3.46
|
per share
|
|
EV:
|
$1.45
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$101
|
M
| |
14.4
|
x EV/EBITDA
|
|
EBIT
|
$16.9
|
M
| |
86.1
|
x EV/EBIT
|
| EPS |
$0.70
| |
42.9
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 667.2 | 579.8 | 520.4 | 392.8 | 408.9 | 302.2 | 215.0 | 147.5 |
| Revenue growth | 15.1% | 11.4% | 32.5% | -3.9% | 35.3% | 40.6% | 45.8% | 59.1% |
| Cost of goods sold | 86.7 | 68.5 | 54.4 | 16.7 | 15.4 | 15.2 | 12.0 | 8.4 |
| Gross profit | 580.5 | 511.2 | 466.0 | 376.1 | 393.5 | 287.0 | 203.0 | 139.0 |
| Gross margin | 87.0% | 88.2% | 89.6% | 95.8% | 96.2% | 95.0% | 94.4% | 94.3% |
| Selling, general and administrative | 377.2 | 304.8 | 200.7 | 153.2 | 154.7 | 137.9 | 106.0 | 89.1 |
| Research and development | 74.6 | 90.5 | 76.0 | 69.1 | 89.2 | 49.6 | 42.8 | 29.1 |
| EBITA | 127.7 | 109.5 | 191.3 | 153.8 | 149.6 | 106.4 | 55.5 | 21.0 |
| EBITA margin | 19.1% | 18.9% | 36.8% | 39.1% | 36.6% | 35.2% | 25.8% | 14.3% |
| Amortization of intangibles | 82.6 | 30.0 | 15.7 | 5.2 | 5.2 | 6.9 | 1.3 | 0.2 |
| EBIT | 45.1 | 79.5 | 175.6 | 148.6 | 144.4 | 99.5 | 54.2 | 20.8 |
| EBIT margin | 6.8% | 13.7% | 33.7% | 37.8% | 35.3% | 32.9% | 25.2% | 14.1% |
| Pre-tax income | 60.7 | 73.2 | 168.6 | 147.5 | 140.2 | 100.6 | 50.4 | 14.6 |
| Income taxes | 0.0 | 19.8 | 41.7 | 34.4 | 29.2 | 43.3 | -40.9 | 0.7 |
| Tax rate | 0.1% | 27.0% | 24.7% | 23.3% | 20.8% | 43.1% | | 4.6% |
| Net income | 60.7 | 53.4 | 127.0 | 113.1 | 111.0 | 57.3 | 91.2 | 13.9 |
| Net margin | 9.1% | 9.2% | 24.4% | 28.8% | 27.1% | 19.0% | 42.4% | 9.5% |
| |
| Diluted EPS | $0.98 | $0.98 | $2.36 | $2.10 | $2.05 | $1.07 | $1.76 | $0.27 |
| Shares outstanding (diluted) | 61.7 | 54.4 | 53.7 | 53.8 | 54.1 | 53.3 | 51.7 | 51.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|